Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + rituximab + cyclophosphamide + etoposide + prednisone
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen, often referred to as Vorinostat-R-CEP, was investigated by Memorial Sloan Kettering Cancer Center for the treatment of elderly patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are ineligible for stem cell transplantation. The regimen replaces procarbazine in the standard R-CEPP protocol with vorinostat, a small molecule histone deacetylase (HDAC) inhibitor. Vorinostat works by inhibiting HDAC enzymes, leading to the accumulation of acetyl groups on histones and non-histone proteins, which alters gene expression and induces cell cycle arrest or apoptosis. The other components include rituximab (an anti-CD20 monoclonal antibody), cyclophosphamide (an alkylating agent), etoposide (a topoisomerase II inhibitor), and prednisone (a corticosteroid). This specific combination was designed to provide an effective alternative for elderly populations who may not tolerate more intensive salvage therapies.
- Other names
- Vorinostat-R-CEPR-CEP + vorinostat
02
Targets
CD20 (B-lymphocyte antigen CD20)CA2 (Carbonic Anhydrase 2)DNAGR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC6 (Histone deacetylase 6)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on vorinostat + rituximab + cyclophosphamide + etoposide + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + rituximab + cyclophosphamide + etoposide + prednisone.